Anti-KIT monoclonal antibody CDX-0159 induces profound and durable mast cell suppression in a healthy volunteer study

Autor: Alvarado, D., Maurer, Marcus, Gedrich, R., Seibel, S.B., Murphy, M.B., Crew, L., Goldstein, J., Crocker, A., Vitale, L.A., Morani, P.A., Thomas, L.J., Hawthorne, T.R., Keler, T., Young, D., Crowley, E., Kankam, M., Heath-Chiozzi, M.

Background: Mast cells (MC) are powerful inflammatory immune sentinel cells that drive numerous allergic, inflammatory, and pruritic disorders when activated. MC-targeted therapies are approved in several disorders, yet many patients have limited ben

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______610::4baf91f646f6af3c5e24a1fb108e1468
https://publica.fraunhofer.de/handle/publica/429749

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Terminology for sample collection in clinical genetic studies.

Autor: Spear, B. B., Heath-Chiozzi, M. E., Barnes, D. M., Cheeseman, K., Shaw, P., Campbell, D. A., McCarthy, A., Ray, S. C., Culver, K., McHale, D., Anderson, D. C., Dahlstroem, C., Hashimoto, L., Sandbrink, R.

Publikováno v: Pharmacogenomics Journal. 2001, Vol. 1 Issue 2, p101. 3p. 1 Chart.

Zidovudine, didanosine, and zalcitabine in the treatment of HIV infection: meta-analyses of the randomised evidence. HIV Trialists' Collaborative Group

Autor: Abrams, D, Allan, D, Antunes, F, Breckenridge, A, Bruun, J, Cameron, W, Carbon, C, Chalmers, I, Chang, H, Chodakewitz, J, Clendenin, N, Clumeck, N, Collier, A, Collins, G, Cooper, E, Cooper, D, Danner, S, D'Aquila, R, DeGruttola, V, DeMasi, R, Dee, L, Deyton, L, Dixon, D, Farthing, C, Feinberg, J, Fischl, M, Flepp, M, Gartland, M, Gatell, J, Gazzard, B, Goebel, F, Gotzsche, P, Gringeri, A, Hall, D, Hamilton, J, Hammer, S, Hartigan, P, Heath-Chiozzi, M, Henry, K, Hill, A, Hirschel, B, Ioannidis, J, Kahn, J, Katlama, C, Katzenstein, D, Killen, J, King, E, de Loes, SK, Kravcik, S, Lange, J, Leavitt, R, Leonard, J, Maeland, A, Mannucci, P, Mathiesen, L, McDade, H, Meibohn, A, Melander, H, Merigan, T, Mulder, J, Myers, M, Neaton, J, Nessling, M, Perrin, L, Pettinelli, C, Phair, J, Phillips, A, Pinching, A, Poppa, A, Power, L, Reiss, P, Richman, D, Rooney, J, Rousseau, F, Rutherford, G, Salgo, M, Sandstrom, E, Saravolatz, L, Savidge, G, Schnittman, S, Schooley, R, Seligmann, M, Simberkoff, M, Skowron, G, Slade, P, Smith, D, Smith, RP, Soriano, V, Stanley, K, Stingl, G, Stoffels, P, Struthers, L, Tierney, C, Thompson, M, Van der Broeck, R, Van Leeuven, R, Van Weverling, G, Veenstra, J, Vella, S, Volberding, P, Weber, J, Winslow, D, Yeni, P, Yeo, J, Dormont, J, Sande, M, Weller, I, Babiker, A, Collins, R, Darbyshire, J, Duncan, W, Foulkes, M, Hughes, M, Peto, R, Peto, T, Walker, S, Grp, HIVTC

Publikováno v: Lancet. 353(9169)

BACKGROUND: To assess the effects of zidovudine, didanosine, and zalcitabine on HIV disease progression and survival, we undertook meta-analyses of individual patient data and tabular data from all randomised trials that compared these agents. METHOD

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______1064::4ed6d8da2b08a8cbc7dd028f2bb13c3d
http://ora.ox.ac.uk/objects/uuid:87578015-55c8-4841-8a9f-6ec439487f4d

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.